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Introduction
The liver is one of the human body’s key organs that regulates 
metabolism and has secretion, storage, and detoxification 
functions. The bile it releases significantly contributes 
to digestion. The liver is the first destination of toxins 
from the intestinal tract. Its cell injuries brought about by 
different toxic agents, including some chemotherapeutic 
agents, thioacetamide, carbon tetrachloride (CC14), 
peroxidized oil, chlorinated hydrocarbons, aflatoxin, 
chronic consumption of alcohol, microbes and viral 
infections (e.g. hepatitis A, B, C, D, etc.), have been 
extensively studied (1). Hepatotoxin-associated liver 
injury makes excretion of bile defective and is reflected 
in increase in toxins’ serum levels (2). Concentrations of 
aspartate transaminase (AST) and alanine transaminase 
(ALT) in cytoplasm and mitochondria of the damaged 
liver cells also increase. The leakage of plasma causes an 
increase in serum hepatospecific enzymes, leading to 
cellular leakage and disturbance of functional integrity 
of the liver cell membrane. In addition, high bilirubin 
concentration in serum is a manifestation of an increase 
in erythrocyte degeneration rate. 
On the other hand, a majority of the hepatotoxic 
chemicals damage liver cells and subsequently kidney 
mostly through lipid peroxidation or other oxidative 
forms. As in the presence of free radicals, lipids peroxidize 
more rapidly, the free radicals scavenging mechanism 
obviously playing an important role in inhibition of 
lipid peroxidation chain reaction (3). Since it is known 
that the overproduction of reactive oxygen species 
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Implication for health policy/practice/research/medical education:
Most drugs that are used in treatment of liver disorders are not effective. Also they have various side effects on kidney. 
Phytochemicals of medicinal plants introduced in this review can be used for production of more effective hepatoprotective 
drugs. Also, they can prevent and treat liver disorders without significant side effects on kidney.
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The liver is a vital organ which plays a major role in the metabolism and excretion of 
xenobiotics from the body, and liver disease is a worldwide health problem. The currently 
available synthetic drugs to treat liver disorders cause further damage to the liver and kidney 
so it is imperative to find new drugs with least side effects. There are a number of treatment 
combinations which are derived from medicinal plants and commonly administered as tonic 
for the liver. In this review, we have introduced most important medicinal plants that are 
used in liver disorders and have least side effects on kidney. In this regards, we have focused 
on their active constituents, effects and trial studies, mechanisms of action, pharmacokinetic 
characteristics, dosages, and toxicity. Amaranthus spinosus L., Glycyrrhiza glabra, Cichorium 
inthybus L., Phyllanthus species (amarus, niruri, emblica), Picrorhiza kurroa, and Silybum 
marianum have been extensively administered for the treatment of liver disorders. The 
introduced medicinal plants can be used for production of new drugs via antioxidant-related 
properties, hepatoprotective activities and least side effects on kidney for the prevention and 
treatment of liver disorders.
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(ROS) reinforces oxidative stress, resulting in an injury 
mechanism associated with the common clinical diseases, 
such as heart disease, kidney and liver injury, diabetes, 
cancer, etc. (4), maintaining the balance between ROS and 
antioxidant enzymes, particularly superoxide dismutase 
(SOD), glutathione peroxidase (GSH-Px) and catalase 
(CAT) is crucial in preventing oxidative stress damages 
(5). The enzymatic antioxidant defense systems, such as 
Cu–Zn, Mn–SOD, CAT and GSH reductase, which are 
natural lipid peroxidation protectors, function by direct or 
sequential ROS removal, thus terminating or diminishing 
this process (6). In order to avoid lipid peroxidation, it is 
very important to maintain the level of GSH, an important 
antioxidant in cytosol involved in detoxification and 
excretion of xenobiotics (7). Out of the xenobiotics, 
CC14 is considered to be a major cause of acute liver cell 
injury via bioactivation trichloromethyl free radicals 
(8). Compounds that increase activity of glutathione 
S-transferase (GST), which metabolizes toxic to non-toxic 
compounds, have an increasingly protective mechanism 
in the liver.
Natural products including medicinal plants and their 
compounds reported to prevent and treat a lot of diseases 
due to fewer side effects on body systems (9-14). Herbal 
extracts could significantly contribute to recovery 
processes of the intoxicated liver and kidney. A huge 
number of plant species have already been examined for 
efficacy against a spectrum of liver diseases (15). From our 
previous studies, we have already reported 26 medicinal 
plants from Iran which have been used for liver disorders, 
as recorded in available ethnobotanical documents (16), 
and we have completely reviewed and introduced twelve 
plant species that are used in Iran’s traditional medicine 
for prevention and treatment of liver disorders (17). In 
this review, we aimed to introduce six medicinal plant 
species used worldwide for prevention and treatment 
of liver disorders that have least side effects on kidney, 
with a focus on their active constituents, their efficacy, 
mechanism of action, pharmacokinetic characteristics, 
dosages, and toxicity. It should also remember that, many 
hepatoprotective herbal drugs, have nephroprotective 
efficacy. Therefore knowledge on medicinal plants with 
liver protective effects  lead to a better understanding of 
their possible nephroprotective efficacy.
Materials and Methods
For this study, online databases including Web of Science, 
PubMed, Scopus, and Science Direct were searched for 
papers published from January 1970 to June 2016. Search 
terms were as follows, used either alone or in combination: 
medicinal plants, traditional medicine, folk medicine, 
hepatoprotective, Iran, liver, renal injury, therapeutic uses, 
antioxidant, compounds, CC14, hepatitis, nephrotoxicity, 
anti-hepatotoxic, and anti-inflammatory. 
Results
Amaranthus spinosus L.
Amaranthus spinosus L. from the Amaranthaceae family, 
commonly called pigweed, is an annual herb found in 
many tropical countries (18). The whole plant is used 
for the treatment of jaundice in Iranian traditional 
medicine (19). It has a high concentration of antioxidant 
components (20,21) and a high nutritive value due to its 
high content of fibers, proteins and essential amino acids, 
particularly lysine (22). Also, it is used as an antimalarial 
and antimicrobial agent and has anti-inflammatory effects 
in hepatic disorders (23,24).
Active constituents
Amaranthus spinosus have many important constituents, 
such as ﬂavonoids, phenolic acids, alkaloids, glycosides, 
steroids, amino acids, terpenoids, lipids, saponins, 
betalains, b-sitosterol, stigmasterol, linoleic acid, rutin, 
catechuic tannins and carotenoids (2). Phytochemical 
analysis of the plant revealed presence of spinoside, a 
new coumaroyl flavone glycoside, as well as xylofuranosyl 
uracil, hydroxycinnamates, quercetin, kaempferol 
glycoside, betalains, betaxanthin, betacyanin, phenolic 
compounds, amaranthine and isoamaranthine, b 
-sitosterolglycoside, campesterol, while hentriacontane, α‐
spinasterol, linoleic acid, rutin and betacarotene, detected 
in the leaves and stems as the prime constituents (18). 
The betalains identified in the stem bark of A. spinosus 
were amaranthine, isoamaranthine, hydroxycinnamates, 
quercetin and kaempferol glycosides (24). It also contains 
amaranthoside, a lignan glycoside, amaricin, a coumaroyl 
adenosine along with stigmasterol glycoside, and betaine 
such as glycinebetaine and trigonelline (2).
Effect and trial researches 
In studies, the whole plant of A. spinosus was evaluated 
for effects against liver disorders, and results indicated 
that serum enzymatic levels of glutamate pyruvate 
transaminase, glutamate oxaloacetate transaminase, 
alkaline phosphatase (ALP) and total bilirubin were 
decreased by A. spinosus extract (ASE) treatments (2). 
Hepatoprotective activity of the 50% ethanol extract of 
the whole plant showed effective against d-galactosamine/
lipopolysaccharide (dGalN/LPS) and against carbon 
tetrachloride (CCL4) induced liver injury in rats (2). 
dGalN/LPS-induced hepatic damage was manifested by 
increasing in the activities of enzymes such as ALP, gamma 
glutamyl transferase, ALT, AST, and lactate dehydrogenase 
and by decreasing in bilirubin level of serum. Pretreatment 
(400 mg/kg) of rats with ASE significantly reversed these 
altered parameters to normal compared to the intoxicated 
group (25). 
Mechanism of action
Activity against CCL4 may be due to the presence 
compounds such as of flavonoids and phenolics in the ASE 
which may have hepatoprotective activities (2). Hence, it 
is possible that the hepatoprotective mechanism of whole 
plant A. spinosus is due to its antioxidant activity (25).
Pharmacokinetic characteristics, dosage/toxicity
From the results it is clear that the ASE has shown a 
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dose dependent response in which 400 mg/kg p.o. shows 
greatest effects compared to the control group (2). 
Cichorium intybus L.
Cichorium intybus from the Asteraceae family, is a 
medicinally important genus native to Europe, tropical 
Asia, and North Africa (26). Various health benefits have 
been reported in these parts of the world. Aqueous root 
extract is used against malaria (27), for the treatment of 
warts (28), against liver diseases and digestive problems 
(29), and as a laxative and diuretic (30,31).
Active constituents
Previous phytochemical studies revealed the presence of 
phenolic acids, flavonoids, anthocyanins, sterols, hydroxyl 
cinnamic acid derivatives, polyamines, sesquiterpene 
lactones, triterpenoids, norisoprenoids and coumarins in 
the aerial parts of Cichorium species (32,33). Also fibers 
such as oligosaccharide and inulin have recently been 
recognized in root of the plant. 
Effects and trial researches 
Evaluations of the biological activity of whole plant 
extract of C. intybus have revealed hepatoprotective 
and antidiabetic activities while the aerial parts have 
antimicrobial, antioxidant and anthelmintic effects 
(31,34,35). Aqueous and alcoholic extracts of C. intybus 
L. showed anti-inflammatory activity against formalin-
induced paw edema in mice (36). The anti-hepatotoxicity, 
anti-inflammatory, gastroprotective properties and 
antioxidant activity of C. intybus L. suggest that C. intybus 
has useful effects on acute pancreatitis (37). The results of 
the total phenolic content assay on the extract, sub-extracts 
and fractions from the roots of C. intybus indicated that 
CH2Cl2, EtOAc and n-BuOH sub-extracts were rich in 
phenolic constituents with significant anti-inflammatory 
and antioxidant effects, possibly even contributing to the 
wound healing process (38). Moreover, C. intybus have 
been shown to possess a wide variety of pharmacological 
properties such as antimicrobial, anti-tumoral, anti-
inflammatory (37,39). Comparing the hepatoprotective 
effects of natural root extract of C. intybus and its root 
callus extracts has been showed that root callus extract 
had better activity against CCL4 hepatotoxicity (40). 
Mechanism of action
Various mechanisms might be involved in the protective 
effects of C. intybus. The total extracts have many 
different components for which there are a wide variety 
of pharmacological effects. C. intybus root extract (its 
ethyl acetate extract) inhibits the expression and activity 
of cyclooxygenase 2 (COX-2) (41). Also C. intybus 
extract (CIE) inhibits angiotensin converting enzyme 
and pancreatic lipase (42). Moreover, reduced levels of 
malondialdehyde and increased levels of antioxidant 
enzymes are the main mechanisms of CIE for preventing 
the development of liver fibrosis induced via CCl4 (43). 
Hepatoprotective, gastroprotective, anti-inflammatory 
actions and free radical scavenging are the major 
properties of C. intybus that are assumed to be related to 
its flavonoids (39).
Pharmacokinetic characteristics, dosage/toxicity
The results also indicated that root extract, especially 
150 mg/kg as the highest test dose, markedly prevented 
necrosis in liver tissue. However, lower doses of 100 were 
only effective to decrease milder forms of liver injures 
like fatty changes and bilirubin content. In oral route, the 
dose of 200 mg/kg showed a significant decrease in levels 
of lipase (24%) and amylase (16%). The dose 200 mg/
kg, i.p. had only effect on inflammatory features such as 
leukocyte infiltration in pancreatitis tissue. 
Glycyrrhiza glabra
Glycyrrhiza glabra (licorice root) originates from the 
Middle East and Mediterranean. Also it has been cultivated 
in Europe since the 16th century (44). The root aqueous 
extract known for its antiviral activity, detoxifying effects 
and anti-allergic (45). It is said to be effective in the 
treatment of bronchitis and other infections mentioned 
above. Moreover, aqueous extract of G. glabra has been 
used to treat patients with hepatitis and is well documented 
in reducing liver transaminases (46).
Active constituents
Glycyrrhizin, as a conjugate of glucuronic acid and 
glycyrrhetinic acid, is one of the most important active 
constituents of G. glabra. Glycyrrhizin is metabolized in 
the liver into 3-mono-glucuronide-glycyrrhetinic acid. It 
is excreted in bile and further metabolized by intestinal 
bacteria into glycyrrhetinic acid (45). Glycyrrhizin has 
antioxidant, immunosuppressive and anti-inflammatory 
effects (46). Other constituents of G. glabra include 
coumarins (umbelliferone, herniarin), triterpenoids, 
flavonoids (isoliquiritin and liquiritin), isoflavonoids 
(glabrol, kumatakenin, isoflavonol, and licoricone), 
phytosterols, and chalcones (47). It also includes 
glycyrrhetic acid, hydroxycoumarins and sterols (46).
Effect and trial researches 
It has been shown that G. glabra has direct 
hepatoprotective effects. Flavonoids of G. glabra provided 
protection to hepatocytes exposed to CCL4 hepatotoxicity. 
The researchers highlighted the anti-inflammatory, 
free-radical quenching, anti-lipid peroxidation, and 
immunosuppressive properties of Glycyrrhiza. Animal 
studies have shown that G. glabra can activate P450 
phase I detoxification reactions and enhance liver 
glucuronidation (45).
Glycyrrhiza glabra exerts antiviral activity in vitro toward 
a number of viruses such as hepatitis A. Also, intravenous 
glycyrrhizin has been shown to be effective on viral 
hepatitis (in particular chronic viral hepatitis) in a double-
blind study. It has shown that G. glabra can stimulate 
endogenous interferon production (47).
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Mechanism of action
Through in vitro studies with human hepatoma cells, 
Crance et al showed that glycyrrhizin inhibited penetration 
of hepatitis A virus likely by altering cell membrane 
fluidity (48). In addition, glycyrrhizin has been shown to 
decrease the release of AST via inhibiting the activation of 
phospholipase A2, as well as via prevention of changes in 
the hepatocyte membrane permeability. Also, glycyrrhizin 
was found to can suppress hepatitis B surface antigen 
(HBsAg) production (45).
Pharmacokinetic characteristics, dosage/toxicity
The pharmacokinetic characteristics of intravenous 
administration of G. glabra has been studied in Europe 
and Asian in patients that have liver diseases, and 
comparable results have been found (49). The drug has 
linear pharmacokinetics up to 200 mg, and steady state 
is achieved after 2 weeks of 200-mg doses administered 
6 times per week (45). G. glabra has a well-known 
pseudoaldosterone effect when large doses are ingested. 
The symptoms of pseudoaldosterone syndrome include 
hypertension, hypokalemia, sodium and water retention, 
low plasma renin activity, and suppressed urine and 
serum aldosterone levels. Edema and worsening of ascites 
are also a result of glycyrrhizin’s aldosterone-like actions. 
The amount of glycyrrhizin needed to produce these 
symptoms is variable. In one study in which fourteen 
healthy volunteers ingested 100-200 g of a licorice 
product (equivalent to approximately 10-4 grams of the 
crude herb or 0.7-1.4 g glycyrrhizinic acid), for one to 
four weeks, plasma rennin activity or urinary aldosterone 
concentrations were decreased in all subjects, revealing a 
significant effect of licorice root on the renin angiotensin- 
aldosterone axis at these doses (47). 
Phyllanthus species (amarus, niruri, emblica)
The Phyllanthus has about 750-800 species found in 
tropical and subtropical regions worldwide (50). A 
substantial number of Phyllanthus species are used 
widely in traditional medicine for the treatment liver 
diseases (51,52). Among different species of Phyllanthus, 
P. amarus is highly regarded in the treatment of liver 
ailments and kidney stones (53,54). P. emblica L. is native 
to India and has been shown to possess widespread 
pharmacological application such as liver disorders 
(7,43). Also, anti-hepatotoxic components present in P. 
niruri such as hypophyllanthin and phyllanthin showed 
hepatoprotective activities (55).
Active constituents
Vitamin C, phyllambic compounds, phenolic compounds, 
and flavonoids are the effective components of Phyllanthus 
species that may effect on oxidative damage (56). P. amarus 
was found to contain phyllanthin and hypophyllanthin 
and the chemical composition analysis indicated that the 
protective effect of P. urinaria extract was primarily due to 
the presence of corilagin and gallic acid (57). Also fruits 
of Phyllanthus have two newly identified hydrolysable 
tannins, emblicanin A and B, which are vitamin C-like. 
(58,59).
Effect and trial researches 
Phyllanthus amarus is a well-known hepatoprotective 
and antiviral agent (60,61). Earlier studies reported that 
P. amarus is a hypoglycemic, diuretic, and hypotensive 
drug for humans (54). The hepatoprotective effect 
of methanolic extract of the leaf of P. amarus against 
ethanol-induced oxidative damage is shown in studies 
using adult male Wistar albino rats. Reduced levels 
of CAT, GSH, and SOD in the liver were significantly 
enhanced by P. amarus treatment (62). In a similar 
study, the ethanolic extract of P. urinaria was reported 
to protect against an acetaminophen overdose by down-
regulating hepatic cytochrome P450 CYP2E1 protein 
(63). The methanolic extract of P. urinaria has also been 
reported to protect against CCl4 -induced liver toxicity via 
elevating the activity of reduced glutathione peroxidase 
(GSH-Px), attenuating the increase in serum glutamate-
oxalate transaminase (GOT), (64), and increasing 
intracellular free Ca2+ concentrations in liver cells (65). 
Also, previous studies have shown the hepatoprotective 
activity of the P. emblica fruit extract against a variety 
of toxins such as CCl4, (56,66-69). Niranthin and 
nirtetralin are reported to possess anti-inflammatory 
and hepatoprotective activities. Cytotoxic effect of these 
compounds on some human cancer cell lines, suggests 
a potential action of Phyllanthus lignans as multidrug 
resistance (MDR) reversing agents (70). Moreover, 
Thyagarajan et al have shown the antiviral properties 
against HBV for the whole plant extract of P. niruri (71). 
Action mechanism 
The main mechanism involved in this protection could 
be associated with its strong capability to reduce the 
intracellular level of ROS (72). Hepatoprotective activity 
of ethanolic extract of P. amarus (EEP) is due to its 
stimulatory effect on both enzymatic and non-enzymatic 
antioxidant systems, as observed in experimental mice. 
Consequently, the damage induced by aflatoxin B1 in the 
liver of mice is suppressed with the administration of EEP 
due to the reduction in the level of ROS, as indicated by 
the reduction in the level of thiobarbituric acid reactive 
substances (TBARS) and repair process in the liver of 
these mice (54).
Pharmacokinetic characteristics, dosage/toxicity
Jayaram et al, studying the effect of P. amarus on beta-
galactosamine-induced hepatotoxicity on isolated rat 
hepatocytes, found that P. amarus by itself was not 
hepatotoxic and at 1 mg/mL concentration it was found 
to be hepatoprotective (73). P. amarus whole plant powder 
administered at a dosage of 0.66 g/kg in rats showed 
hepatoprotective activity against CCl4-induced liver 
damage (74). In another study, both 250 and 500 mg/
kg doses of P. amarus extract significantly reduced the 
ethanol-induced elevated levels of lipid hydroperoxide 
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(LPO). More so, the 250 mg/kg extract markedly improved 
the ethanol-induced reduction in GSH, SOD and CAT 
levels, while the 500 mg/kg extract exerted a further 
decrease. The restoration of oxidant/antioxidant balance 
is further reflected in the improved hepatic activities of 
transaminases and ALP. A dose dependent improvement 
in hepatic AST, ALT and ALP activities, with a concomitant 
reduction in the plasma activity of ALT and AST, was seen 
with co-treatment of 250 mg/kg extract with ethanol, and 
even more so with 500 mg/kg. (75). 
Picrorhiza kurroa
Picrorhiza kurroa from the Scrophulariaceae family, as 
a small perennial herb, grows in northwest India on the 
slopes of the Himalayas (76). It is an important herb in the 
traditional Ayurvedic system of medicine, and has been 
used to treat bronchial and liver problems (49). Picrorhiza 
is poorly soluble in water and so is usually not taken as a 
tea. It is soluble in ethanol and it can be taken in tincture 
form (77).
Active constituents
The most important active constituents of Picrorhiza are 
the iridoid glycoside picrosides I, II, III, and kutkoside, 
known collectively as kutkin (78). Many other active 
constituents have been identified, including flavonoids, 
triterpenes, alkaloids, and coumarins such as apocynin, 
glycosides, nine cucurbitacin, drosin, and triterpenoid 
ursolic acid (79). 
Effect and trial researches 
Picrorhiza has been shown to protect liver cells from a 
wide variety of inflictions including amanita poisoning 
(80,81), carbon tetrachloride (82-84), galactosamine 
(85,86), ethanol (87), aflatoxin B1 (88), acetaminophen 
(89), thioacetamide (90), oxytetracyline (91), and 
monocrotaline (92) in both in vitro and in vivo 
experiments. When compared with silymarin, the 
hepatoprotective effect was found to be similar, or in 
many cases, superior to the effect of silymarin (87,90). 
Dwivedi et al have shown significant hepatoprotective 
properties of picroliv using models such as monocrotaline 
and CCl4-induced liver injury in rats (86). Shukla et al 
compared picroliv with silymarin in animal models and 
found potent anticholestatic and choleretic functions (93). 
Chander et al also found hepatoprotective properties in P. 
kurroa (94).
Picrorhiza may be valuable in the treatment of viral 
hepatitis. In vitro studies have shown anti-viral activity of 
P. kurroa (95) and the existing literature suggests that P. 
kurroa is a powerful immuno-modulator rather than an 
antiviral drug in liver diseases (96). 
Mechanism of action
It has been reported that flavonoids, triterpenes, alkaloids, 
and coumarins may be responsible for their antioxidant 
and hepatoprotective effects (97-99). Also, flavonoids are 
known to be antioxidants, free radical scavengers, and anti-
lipoperoxidants, leading to hepatoprotection (100). In the 
previous reports, extracted beta-sitosterol of P. kurroa was 
found to have antioxidant (101,102), anti-inflammatory 
(103-105), and proliferative (106) activities. Moreover, 
it was found that picroside-I and kutkoside inhibited 
the non-enzymatic generation of O2-anions, oxidative 
malonaldehyde (MDA), and scavenged superoxide (O2) 
anions. In other words, P. kurroa has antioxidant activity 
similar to SOD, metal-ion chelators, and xanthine oxidase 
inhibitors (107). 
Like silymarin, P. kurroa compounds may have an 
effect on liver regeneration. One study demonstrated 
stimulation of nucleic acid and protein synthesis in liver 
of rats with oral administration of P. kurroa. The authors 
stated the results were comparable to silymarin (108). 
Also, P. kurroa has been shown to protect ethynylestradiol 
and acetaminophen -induced cholestasis, maintaining 
both bile volume and flow (109). 
Pharmacokinetic characteristics, dosage/toxicity
The usual adult dosage P. kurroa is 400 to 1500 mg/d, 
although daily doses as high as 3.5 g/d have been 
recommended for fevers (110). By comparison, the 
maximum dose achievable with oral ingestion of P. kurroa 
root is about 3-6 mg/kg (111). No effects on cellular and 
humoral immunity were reported after treatment with 
apocynin as an active constituent of P. kurroa (112,113).
Silybum marianum 
The genus Silybum is a member of the Asteraceae 
family (Compositae) and grows in India, China, South 
America, Africa, and Australia, among other countries 
(114). S. marianum, from the fruits of the milk thistle, 
has been used as a treatment for hepatobiliary diseases 
since the 16th century (115). It has been shown to have 
clinical applications in the treatment of toxic hepatitis, 
alcoholic liver diseases, fatty liver, cirrhosis, viral hepatitis 
and liver regenerating effects (116,117). The excellent 
hepatoprotective activity of silymarin, besides its 
immunomodulatory, anti-lipid peroxidative, antifibrotic, 
membrane stabilizing and anti-inflammatory activities, 
makes it a very promising drug of natural origin (118).
Active constituents
The plant consists of approximately 60%-80% of the 
silymarin flavonolignans and approximately 20%-30% of 
a chemically undefined fraction, so comprised mostly of 
polymeric and oxidized polyphenolic compounds (118). 
Silymarin is a polyphenolic flavonoid, the most prevalent 
component silybin (50%-60% of silymarin), which is the 
most active photochemical and is largely responsible for 
the claimed benefit of the silymarin (119,120). Besides 
silybin, considerable amounts of other flavonolignans are 
present in the silymarin complex such as dehydrosilybin, 
silydianin, silychristin, isosilybin, and a few taxifolin. The 
seeds also contain essential fatty acids, trimethylglycine, 
and betaine, that may contribute to silymarin’s anti-
inflammatory and hepatoprotective effects (121-124).
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Effects and trial researches
Hepatoprotective effects of silymarin on carbon 
tetrachloride (125,126), phenylhydrazine (127,128), 
tert-Butyl hydroperoxide (129), thioacetamide 
(130,131), galactosamine (129,132), paracetamol (133), 
erythromycin estolate (134,135), microcystin (136) and 
amanita phalloids toxin (137) have been shown. Numerous 
studies have suggested that silymarin has significant anti-
inflammatory effects on hepatic tissue and that it regulates 
inflammatory mediators such as tumor necrosis factor 
(TNF) (120), TNF-alpha (138), interleukin-6, nitrous 
oxide, and interleukin-1 receptor antagonist (139). 
Silybin [4-10 mol/L concentration] was found to reduce 
the proliferation of freshly isolated hepatic cells by about 
75%. It also reduced the conversion of stellate cells into 
myofibroblasts and down-regulated the gene expression 
of extracellular matrix components necessary for fibrosis 
(140). 
Mechanism of action
Silymarin has been found to inhibit the formation of 
leukotrienes via its inhibition of the lipoxygenase. These 
leukotrienes are known as the most damaging chemicals 
found to man (141). Studies also demonstrated that 
silymarin stabilized mast cells (142), decreased the activity 
of tumor promoters (143,144), shows anti-inflammatory 
(145) modulated immune functions (146) and is anti-
fibrotic (117). One of the mechanisms to explain the ability 
of silymarin to stimulate the regeneration of hepatic tissue 
is the increase in protein synthesis in damaged livers. 
Silymarin led to increase in protein and mRNA of phases 
of cell cycle. Expression of TGFα, TGFβ1, and HGF was 
also enhanced (147,148). Finally, silymarin may inhibit 
the activity of uridine diphosphoglucuronosyl transferase 
and cytochrome P450 3A4 in human hepatocytes, so 
inhibiting the metabolism of certain drugs (148,149). 
Theoretically, silymarin may decrease the clearance of 
drugs that undergo glucuronidation and increase the 
clearance of estrogen by inhibiting glucuronidase (150).
Pharmacokinetic characteristics, dosage/toxicity 
Silymarin has been proven to be as a non-toxic drug when 
administered for short periods of time at high doses, 
and the active components of silymarin had protective 
effects against hepatotoxic actions of drugs (151). Human 
studies have shown that silymarin is generally without 
side-effects. for is 240- 900 mg/d in two or three doses are 
the typical adult dosage. Nausea and meteorism can be 
seen in patients treated with 360 mg/day (152). At higher 
doses, 240 mg/d, silymarin may produce a laxative effect 
due to increased bile flow and secretion. Also stomach 
upset, heartburn and transient headaches were reported 
(153). Other symptoms have included nausea, epigastric 
discomfort, urticaria and arthralgia (154). 
Implications and mechanisms
Most of hepatotoxic damage is mainly due to lipid 
peroxidation and other oxidative damages. Scavenging of 
free radicals is one of the main anti-oxidative mechanisms 
to inhibit the chain reaction of lipid peroxidation. Many 
studies have demonstrated that overproduction of 
ROS can further aggravate the oxidative stress and the 
result is a unifying mechanism of injury that occurs in 
development of many clinical disease processes, such as 
heart disease, diabetes, liver injury, cancer, aging, etc. 
(155-159). Maintaining the balance between ROS and 
antioxidant enzymes, especially SOD, CAT and GPx, is 
crucial and could serve in preventing damage by oxidative 
stress (160-162). In hepatic cells, enzymatic antioxidant 
systems act by removal of ROS, thereby terminating their 
activities (163,164). 
The plants reviewed in this article mainly contain 
phenolic and flavonoid compounds which are known 
to be antioxidants, anti-lipoperoxidants and free radical 
scavengers, leading to hepatoprotection. For example, 
picrorhiza main constituents, picroside-I and kutkoside, 
inhibit the non-enzymatic generation of O2-anions and 
scavenge superoxide (O2) anions and level of GSH, SOD, 
and CAT in the liver. Also Phyllanthus species, through 
their strong capability to reduce the intracellular level 
of ROS via the reduction in the level of TBARS and the 
induction of recovery and repair process in the liver, can be 
beneficial for prevention and treatment of liver disorders. 
Cichoric acid as a main compound of C. intybus reduced 
the intracellular ROS. Also hydroxycinnamic acids and 
flavonoids are among the dominating compounds of 
CIE, and can significantly attenuate ROS induction. They 
can have a significant antioxidant effect on low density 
lipoprotein (165).
CCl4, as another of the most common hepatotoxins, 
is biotransformed to trichloromethyl radical under 
the action of cytochrome P450 in the microsomal 
compartment of the liver (166). Glycyrrhiza flavonoids 
provided protection to hepatocytes exposed to carbon 
tetrachloride-induced hepatotoxicity by enhancing 
hepatic glucuronidation and activating P450 phase I 
detoxification reactions. Hepatoprotective activity of the 
50% ethanol extract of A. spinosus was identified against 
d-galactosamine/lipopolysaccharide (dGalN/LPS) and 
against CCl4 (2). Moreover, hepatoprotective activity of 
silymarin against toxicity caused by CCl4, phalloiride, 
acetaminophen, ethanol, and D-galactosamine has been 
demonstrated. Stimulation of polymerase I and rRNA 
transcription, and protecting the cell membrane from 
radical-induced damage, were mechanisms of action 
of silymarin. Furthermore, flavonoid compounds of C. 
intybus could prevent the development of liver fibrosis 
induced by CCl4 via increased levels of antioxidant 
enzymes (43).
Conclusion
Since treatment of liver disorders, especially viral hepatitis 
or other chronic liver diseases by available drugs is not 
adequate and is with side effects on kidney, it is necessary 
to produce new hepatoprotective drugs. The introduced 
medicinal plants via antioxidant-related properties and 
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hepatoprotective activities can be used for production of 
new drugs to prevent and treat liver diseases with least 
side effects on kidney. Therefore, we recommend further 
research, including clinical trials, to evaluate the effects 
of the introduced phytochemicals in this review, for 
production of more effective hepatoprotective drugs. 
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